The immune-inflammatory pathophysiology of fibromyalgia: Increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines

Psychoneuroendocrinology

Volumn 24, Issue 4, 1999, Pages 371-383

  Maes, Michael ^a,b,c   Libbrecht, Isabelle ^a   Van Hunsel, Fran ^a   Lin, Ai Hua ^a,d   De Clerck, Luc ^d   Stevens, Wim ^d   Kenis, Gunter ^e   De Jongh, Raf ^e   Bosmans, Eugene ^f   Neels, Hugo ^g  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b VANDERBILT UNIVERSITY   (United States)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e AZ Campus Oost Limburg ^*  (Belgium)

^f Eurogenetics   (Belgium)

^g Laboratory of Clinical Biology   (Belgium)

Author keywords

Cytokines; Depression; Fibromyalgia; gp130; Interleukin 6; Neurokines

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 130; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; FIBROMYALGIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INCIDENCE; MUSCULOSKELETAL DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RATING SCALE; SIGNAL TRANSDUCTION;

ANTIGENS, CD; ANTIGENS, CD8; CYTOKINE RECEPTOR GP130; CYTOKINES; FEMALE; FIBROMYALGIA; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; RECEPTORS, INTERLEUKIN-6; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION;

EID: 0032934378     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(98)00087-0     Document Type: Article

References (56)

1. Bluthé R.M., Crestani F., Kelley K.W., Dantzer R. Mechanisms of the behavioral effects of interleukin 1. Ann. New York Acad. Sci. 650:1992;268-275.
2. Bock G.R., Marsh J., Widdows K. Polyfunctional Cytokines: IL-6 and LIF; Ciba Foundation Symposium 167. 1992;Wiley, Chichester.
3. Cannon J.G. Cytokines in aging and muscle homeostasis. J. Gerontol. 50:1995;120-123.
4. Caro X.J. Is there an immunologic component to the fibrositis syndrome? Rheum. Dis. Clin. North Am. 15:1989;169-186.
5. Cunha F.Q., Poole S., Lorenzetti B.B., Ferreira S.H. The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 107:1992;660-664.
6. Czlonkowski A., Stein C., Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur. J. Pharmacol. 242:1993;229-235.
7. Dayer J.-M., Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw. 5:1994;563-571.
8. DeLeo J.A., Colburn R.W., Nichols M., Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J. Interferon Cytokine Res. 16:1996;695-700.
9. Dinarello C.A. The biological properties of interleukin-1. Eur. Cytokine Netw. 5:1994;517-531.
10. Enestrom S., Bengtsson A., Frodin T. Dermal IgG deposits and increase of mast cells in patients with fibromyalgia - relevant findings or epiphenomena? Scand. J. Rheumatol. 26:1997;308-313.
11. Fann M.J., Patterson P.H. Neuropoietic cytokines and activin A differently regulate the phenotype of cultured sympathetic neurons. Proc. Natl. Acad. Sci. USA. 91:1994;43-47.
12. Ferreira S.H., Lorenzetti B.B., Bristow A.F., Poole S. Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature. 25:1988;698-700.
13. Goldenberg D.L., Felson D.T., Dinerman H. A randomized controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 29:1986;1371-1377.
14. Granges G., Zilko P., Littlejohn G.O. Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. J. Rheumatol. 21:1994;523-529.
15. Gruber A.J., Hudson J.I., Pope H.G. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Psychiatr. Clin. North Am. 19:1996;351-369.
16. Hader N., Rimon D., Kinarty A., Lahat N. Altered interleukin-2 secretion in patients with primary fibromyalgia syndrome. Arthritis Rheum. 34:1991;866-872.
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-61.
18. Hasegawa M., Sato S., Fujimoto M., Ihn H., Kikuchi K., Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25:1998;308-313.
19. Hawley D.J., Wolfe F. Depression is not more common in rheumatoid arthritis: a 10-year longitudinal study of 6153 patients with rheumatic disease. J. Rheumatol. 20:1993;2025-2031.
20. Hernanz W., Valenzuela A., Quijada J., Garcia A., De La Iglesia J.L., Gutierrez A., Povedano J., Moreno I., Sanchez B. Lymphocyte subpopulations in patients with primary fibromyalgia. J. Rheumatol. 21:1994;2122-2124.
21. Hirota H., Kiyama H., Kishimoto T., Taga T. Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J. Exp. Med. 183:1996;2627-2634.
22. Hudson J.I., Hudson M.S., Pliner L.F., Goldenberg D.L., Pope H.G. Jr. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am. J. Psychiatry. 142:1985;441-446.
23. Hudson J.I., Pope H.G. Fibromyalgia and psychopathology: is fibromyalgia a form of affective spectrum disorder? J. Rheumatol. (suppl.). 19:1989;15-22.
24. Hudson J.I., Goldenberg D.L., Pope H.G., Keck P.E., Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am. J. Med. 92:1992;363-367.
25. Ip N.Y., Nye S.H., Boulton T.G., Davis S., Taga T., Li Y., Birren S.J., Yasukawa K., Kishimoto T., Anderson D.J., Stahl N., Yancopoulos G.D. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell. 69:1992;1121-1132.
26. Kalyan-Raman U.P., Kalyan-Raman K., Yunus M.B., Masi A.T. Muscle pathology in primary fibromyalgia syndrome: a light microscopic, histochemical and ultrastructural study. J. Rheumatol. 11:1984;808-813.
27. Kim H.S., Degiannis D., Raskova J., Raska K. Cyclosporine A and prednisolone inhibit lectin- and alloantigen-induced release of sCD8: correlation with proliferative responses. Clin. Immunol. Immunopathol. 60:1991;27-39.
28. Krag N.J., Norregaard J., Larsen J.K., Danneskiold-Samsoe B. A blinded controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatrica Scand. 89:1994;370-375.
29. Li M., Sendtner M., Smith A. Essential function of LIF receptor in motor neurons. Nature. 378:1995;724-727.
30. Lipnick R.N., Sfikakis P.P., Klipple G.L., Tsokos G.C. Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis. Clin. Immunol. Immunopathol. 68:1993;64-67.
31. Littlejohn G.O., Weinstein C., Helme R.D. Increased neurogenic inflammation in fibrositis syndrome. J. Rheumatol. 14:1987;1022-1025.
32. Maes M. The immune pathophysiology of major depression. Honig A., van Praag H.M. Depression, Neurobiological, Psychopathological and Therapeutic Advances. 1997;197-215 Wiley, Chichester.
33. Matsuda T., Fukada T., Takahashi-Tezuka M., Okuyama Y., Fujitani Y., Hanazono Y., Hirai H., Hirano T. Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association. J. Biol. Chem. 12:1995;11037-11039.
34. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1:1975;277-299.
35. Moldofsky H. Sleep, neuroimmune and neuroendocrine functions in fibromyalgia and chronic fatigue syndrome. Adv. Neuroimmunol. 5:1995;39-56.
36. Murakami-Mori K., Taga T., Kishimoto T., Nakamura S. The soluble form of the IL-6 receptor (sIL-6Rα) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for IL-6Rα-induced AIDS-KS cell growth. Int. Immunol. 8:1996;595-602.
37. Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishihara Y., Yancopoulos G.D., Taga T., Kishimoto T. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 82:1993;1120-1126.
38. Oka T., Aou S., Hori T. Intracerebroventricular injection of interleukin-1β enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats. Brain Res. 656:1994;236-244.
39. Oka T., Oka K., Hosoi M., Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res. 692:1995;123-128.
40. Peters M., Jacobs S., Ehlers M., Vollmer P., Mullberg J., Wolf E., Brem G., Meyer-zum-Buschenfelde K.H., Rose-John S. The function of the soluble interleukin-6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med. 183:1996;1399-1406.
41. Poole S., Cunha F.Q., Selkirk S., Lorenzetti B.B., Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br. J. Pharmacol. 115:1995;684-688.
42. Quesniaux V.F.J. Interleukin-11. Cavaillon J.-M. Les Cytokines. 1996;253-266 Masson, Paris.
43. Reiffenberger D.H., Amundson L.H. Fibromyalgia syndrome: a review. Am. Fam. Phys. 53:1996;1698-1712.
44. Russell I.J., Michalek J.E., Vipraio G.A., Fletcher E.M., Javors M.A., Bowden C.A. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J. Rheumatol. 19:1992;104-109.
45. Schochat T., Croft P., Raspe H. The epidemiology of fibromyalgia. Workshop of the Standing Committee on Epidemiology European League Against Rheumatism, Bad Säckingen, 19-21, November 1992. Br. J. Rheumatol. 33:1994;783-786.
46. Sendtner M., Carroll P., Holtmann B., Hughes R.A., Thoenen H. Ciliary neurotrophic factor. J. Neurobiol. 25:1994;1436-1453.
47. Sims J.S., Dower S.K. Interleukin-1 receptors. Eur. Cytokine Netw. 5:1994;539-546.
48. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Whelan A., Cosyns P., DeJong R., Maes M. The inflammatory response system and the availability of tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 49:1998;211-219.
49. Spath-Schwalbe E., Hansen K., Schmidt F., Schrezenmeier H., Marshall L., Burger K., Fehm H.L., Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Clin. Endocrinol. Metab. 83:1998;1573-1579.
50. Vakakis N., Bower J., Austin L. In vitro myoblast to myotube transformations in the presence of leukemia inhibitory factor. Neurochem. Int. 27:1995;329-335.
51. Watkins L.R., Wiertelak E.P., Goehler L.E., Smith K.P., Martin D., Maier S.F. Characterization of cytokine-induced hyperalgesia. Brain Res. 654:1994;15-26.
52. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P. et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 33:1990;160-172.
53. Xu X.J., Hao J.X., Andell-Jonsson S., Poli V., Bartfai T., Wiesenfeld-Hallin Z. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine. 9:1997;1028-1033.
54. Yunus M.B., Kalyan-Raman U.P., Kalyan-Raman K., Masi A.T. Pathologic changes in muscle in primary fibromyalgia syndrome. Am. J. Med. 29:1986;38-42.
55. Yunus M.B., Hussey F.X., Aldag J.C. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study. J. Rheumatol. 20:1993;1557-1560.
56. Zhou Y., Horiuchi S., Yamamoto M., Yamamoto N. Elevated serum levels of the soluble form of gp130, the IL-6 signal transducer, in HTLV-1 infection and no involvement of alternative splicing for its generation. Microbiol. Immunol. 42:1998;109-116.